- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03086824
A Safety Evaluation of MR-guided Focused Ultrasound Treatment for Palliative Pain Control of Bone Metastases
March 16, 2017 updated by: Jo-Ting Tsai, Taipei Medical University Shuang Ho Hospital
The purpose of this study is to investigate the safety and effectiveness of subjects receiving MR-guided Focused Ultrasound (MRgFUS) treatment for painful bone metastases.
This study will evaluate treatment response and clinically significant adverse events.
Other relevant data may be documented as well.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
This proposed study will be performed in full compliance with all applicable privacy rules and regulations, and their implementations at participating site(s).
All subjects planned to undergo the MRgFUS procedure at Taipei Medical University Hospital will be offered informed consent so they can be included in this Study.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 110
- Department of Radiation Oncology, Taipei Medical University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women age 20 and older.
- Patients who are able and willing to give consent and able to attend all study visits.
- Patients who are suffering from symptoms of bone metastases: Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician, those for whom their treating physician would not prescribe radiation or additional radiation treatments, and those patients who refuse additional radiation therapy.
- Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication.
- Targeted bone/tumor interface are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3-L5), Sacral vertebra (S1-S5).
- Patient whose targeted lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.
- Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible.
- Patients on ongoing chemotherapy regimen at the time of eligibility: 1) with same chemotherapy regimen (as documented from patient medical dossier, 2) worst pain NRS still ≥ 4, and 3) do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study. Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.
- No radiation therapy to targeted (most painful) lesion in the past two weeks.
- Bisphosphonate intake should remain stable throughout the study duration. -
Exclusion Criteria:
- Patients who either Need surgical stabilization of the affected bony structure or Targeted tumor is at an impending fracture site or Surgical stabilization of tumor site with metallic hardware.
- KPS (Karnofsky performance scale) Score < 60.
- Unable to communicate sensations during the ExAblate treatment.
- Target (treated) tumor is less then 10-mm from nerve bundles, bowels or bladder.
- Patients with acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.
- Severe cerebrovascular disease (multiple CVA or CVA within 6 months).
- Patients with unstable cardiac status (e.g. unstable angina pectoris, myocardial infarction within 6 months, congestive heart failure NYHA Class IV, on arrhythmic drugs).
- Severe hypertension (diastolic BP > 100 mmHg on medication).
- Patients on dialysis.
- Patients with standard contraindications for MRI or MRI contrast agents. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MRgFUS
Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Treated-related Adverse Events
Time Frame: 12-months
|
12-months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline Quality of Life Questionnaire
Time Frame: 1day, 3days, 1-week, 2-weeks, 1-month, 2-months, 3-months, 6-months, 9-months, 12-months
|
1day, 3days, 1-week, 2-weeks, 1-month, 2-months, 3-months, 6-months, 9-months, 12-months
|
Change from baseline Pain Score
Time Frame: 1day, 3days, 1-week, 2-weeks, 1-month, 2-months, 3-months, 6-months, 9-months, 12-months
|
1day, 3days, 1-week, 2-weeks, 1-month, 2-months, 3-months, 6-months, 9-months, 12-months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 12, 2014
Primary Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
December 7, 2016
First Submitted That Met QC Criteria
March 16, 2017
First Posted (Actual)
March 22, 2017
Study Record Updates
Last Update Posted (Actual)
March 22, 2017
Last Update Submitted That Met QC Criteria
March 16, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMU-SHH-2014-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Guided Interventional Procedures
-
University Hospital, GrenobleTIMC-IMAGCompletedMagnetic Resonance Imaging | Robotic Surgical ProceduresFrance
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Aarhus University HospitalWithdrawnMagnetic ResonanceDenmark
-
KK Women's and Children's HospitalRecruitingUltrasound-guided Neuraxial ProceduresSingapore
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingMagnetic Resonance ImagingFrance
-
Insel Gruppe AG, University Hospital BernRecruitingMagnetic Resonance SpectroscopySwitzerland
-
Jessa HospitalActive, not recruitingMagnetic Resonance ImagingBelgium
-
BayerCompletedMagnetic Resonance ImagingUnited States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
-
Boston Scientific CorporationCompletedMagnetic Resonance ImagingSpain, Hong Kong, Germany, Israel, United Kingdom, Italy, United States, Malaysia, Belgium
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
Clinical Trials on magnetic resonance-guided focused ultrasound
-
Rambam Health Care CampusUnknownAmputation | Phantom Limb Pain | Residual LimbsIsrael
-
Imperial College LondonInSightecWithdrawnPregnancy | Uterine FibroidsUnited Kingdom
-
University Health Network, TorontoCanadian Cancer Society (CCS); Brain CanadaRecruitingBrain Neoplasms | Liquid BiopsyCanada
-
Yonsei UniversityCompletedLevodopa Induced Dyskinesia in Patients With Parkinson's DiseaseKorea, Republic of
-
UMC UtrechtTerminated
-
University Health Network, TorontoUniversité de SherbrookeRecruiting
-
InSightecCompletedUterine Fibroids | Uterine LeiomyomaUnited States, Canada
-
University of Roma La SapienzaAvailableCancer | Pancreas | Locally Advanced Pancreatic Cancer | Non-invasive TreatmentItaly
-
Ohio State UniversityNot yet recruitingAnxiety | Medication-refractory Focal-onset EpilepsyUnited States
-
InSightecRecruitingGlioblastoma | Glioma, MalignantItaly, Spain